30/09/2024 – AB Science announces today the success of a capital increase by private placement for an amount of 5 million euros Download PDF Post navigationPreviousPrevious post:AB Science provides an update on the microtubule program AB8939NextNext post:AB Science announces a slight delay in the publication of its 2024 half-year financial reportRelated PostsSummary of the webcast held on January 28, 2025January 29, 2025Summary of the webcast held on December 16, 2024December 17, 2024AB Science webcast of December 16, 2024December 16, 2024Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CETDecember 11, 2024AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell diseaseOctober 28, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSOctober 17, 2024
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell diseaseOctober 28, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSOctober 17, 2024
